Abstract
Background: There is a growing body of pre-clinical evidence suggesting that lithium (Li) may protect neurons from a range of neurotoxic insults, hence the term neuroprotective effects. Does Li have similar effects also in human subjects? Methods: We reviewed the neuroimaging literature investigating the association between Li treatment and brain structure. Results: There is level I evidence for positive association between Li treatment and brain grey matter volume, which is one of the most replicated neuroimaging findings. It has been reported in the majority of cross sectional studies, all 8 prospective studies, including a randomized controlled trial as well as in 2 meta-analyses and one mega-analysis. The association between Li treatment and grey matter volume occurs regardless of mood state, diagnostic subtype, presence or absence of concomitant medications. It was documented in multiple brain regions, including hippocampus, amygdala, anterior cingulate, subgenual cingulate, inferior frontal gyrus, postcentral gyrus, habenula. Conclusion: Although some methodological and clinical issues complicate the interpretation of findings, there is robust and highly replicated level 1 evidence for positive association between Li treatment and grey matter volumes. These "neuroprotective" effects of Li have been shown even in healthy subjects and appear independent of prophylactic treatment response. Consequently, Li might help maintain brain health even in patients without bipolar disorders and could possibly demonstrate diseasemodifying properties in neurodegenerative disorders.
Keywords: Amygdala, cerebral cortex, hippocampus, lithium, magnetic resonance imaging, neuroprotection, neurodegeneration.
Current Alzheimer Research
Title:Neuroprotective Effects of Lithium in Human Brain? Food for Thought
Volume: 13 Issue: 8
Author(s): Tomas Hajek and Michael W. Weiner
Affiliation:
Keywords: Amygdala, cerebral cortex, hippocampus, lithium, magnetic resonance imaging, neuroprotection, neurodegeneration.
Abstract: Background: There is a growing body of pre-clinical evidence suggesting that lithium (Li) may protect neurons from a range of neurotoxic insults, hence the term neuroprotective effects. Does Li have similar effects also in human subjects? Methods: We reviewed the neuroimaging literature investigating the association between Li treatment and brain structure. Results: There is level I evidence for positive association between Li treatment and brain grey matter volume, which is one of the most replicated neuroimaging findings. It has been reported in the majority of cross sectional studies, all 8 prospective studies, including a randomized controlled trial as well as in 2 meta-analyses and one mega-analysis. The association between Li treatment and grey matter volume occurs regardless of mood state, diagnostic subtype, presence or absence of concomitant medications. It was documented in multiple brain regions, including hippocampus, amygdala, anterior cingulate, subgenual cingulate, inferior frontal gyrus, postcentral gyrus, habenula. Conclusion: Although some methodological and clinical issues complicate the interpretation of findings, there is robust and highly replicated level 1 evidence for positive association between Li treatment and grey matter volumes. These "neuroprotective" effects of Li have been shown even in healthy subjects and appear independent of prophylactic treatment response. Consequently, Li might help maintain brain health even in patients without bipolar disorders and could possibly demonstrate diseasemodifying properties in neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Hajek Tomas and W. Weiner Michael, Neuroprotective Effects of Lithium in Human Brain? Food for Thought, Current Alzheimer Research 2016; 13 (8) . https://dx.doi.org/10.2174/1567205013666160219112712
DOI https://dx.doi.org/10.2174/1567205013666160219112712 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging
The thematic issue, Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging, aims to bridge the gap between advanced computational techniques and clinical practice in Alzheimer’s disease research. Alzheimer’s disease poses significant challenges in early diagnosis, disease progression monitoring, and predicting treatment efficacy. ...read more
Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies
The increasing burden of age-related neurodegenerative diseases demands an immediate and pressing need for research in all aspects, from molecular mechanisms to therapeutic interventions. The special issue in Current Alzheimer Research "Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies" aims to highlight the summary of state-of-the-art ...read more
Leading Alzheimer Disease Prevention with Precision Health Strategies.
The rising number of patients with Alzheimer’s disease (AD) is a concerning reality in our society. Despite tremendous public-private efforts, finding an appropriate treatment for Alzheimer’s disease prevention has not been successful. One of the reasons behind this failure is the urge to find “a treatment that fits all sizes”, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders
Current Drug Metabolism Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Editorial [Hot Topic: Protease Inhibitors in Drug Discovery (Guest Editor: Francis X. Tavares)]
Current Topics in Medicinal Chemistry The Role of Melatonin in Rheumatic Diseases
Infectious Disorders - Drug Targets A Peptide Based Pro-Drug Ameliorates Amyloid-β Induced Neuronal Apoptosis in In Vitro SH-SY5Y Cells
Current Alzheimer Research Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design The Antidiabetic Potential of Quercetin: Underlying Mechanisms
Current Medicinal Chemistry Neuropsychiatric and Cognitive Symptoms in Spinocerebellar Ataxia: Relationship to Neuropathological Differences
Current Psychiatry Reviews Preface
Current Pharmaceutical Design Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Microglia-Neuron Interaction in Inflammatory and Degenerative Diseases: Role of Cholinergic and Noradrenergic Systems
CNS & Neurological Disorders - Drug Targets Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design BACE Inhibitors as Potential Drugs for the Treatment of Alzheimers Disease: Focus on Bioactivity
Recent Patents on CNS Drug Discovery (Discontinued) Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors
Current Neuropharmacology Mechanisms of Control of Neuron Survival by the Endocannabinoid System
Current Pharmaceutical Design